pharmacovigilance

Clinical trials, no matter how large, test a drug in a few thousand carefully selected people for a limited time. Once a medicine is approved, it may be taken by millions of ordinary patients for years, with other illnesses and other drugs in the mix. Pharmacovigilance is the ongoing watch over a drug's safety after it reaches the real world — the discipline of noticing harms that the trials were too small or too short to catch.

It works by collecting and analyzing reports of suspected adverse drug reactions from doctors, pharmacists, patients, and manufacturers, and pooling them in national and international databases. Statisticians look for signals — a side effect appearing more often than chance would predict — and investigate whether the drug is truly the cause. When a real risk is confirmed, regulators can update the label, add warnings, restrict use, or, in serious cases, withdraw the drug from the market.

Pharmacovigilance is sometimes called phase IV, the surveillance that never ends. Its honest limitation is that it relies on people noticing and reporting harm, so rare or slow-developing effects can take years to surface. It is the reason a drug's safety profile is never truly final at the moment of approval — it keeps being written as long as the drug is used.